RPg Family Wealth Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

RPg Family Wealth Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,500	Closed	-$41.8K	–	276
2017 Q2	$41.8K	Buy	1,500 +500	+50%	+$14.9K	0.04%	178
2017 Q1	$34.4K	Sell	1,000 -1,000	-50%	-$35.3K	0.03%	170
2016 Q4	$57.7K	Buy	2,000 +1,000	+100%	+$26.5K	0.05%	111
2016 Q3	$31.8K	Sell	1,000 -1,000	-50%	-$33.9K	0.02%	147
2016 Q2	$64.9K	Hold	2,000	–	–	0.03%	109
2016 Q1	$55.9K	Buy	+2,000	New	+$43.6K	0.04%	127

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RPg Family Wealth Advisory's ACAD Position: Q3 2017 in Review

RPg Family Wealth Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 1,500 shares — an estimated $41.8K sold.

RPg Family Wealth Advisory first reported a position in ACAD in Q1 2016 and held it in 6 quarters. The position peaked at $64.9K in Q2 2016. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

RPg Family Wealth Advisory reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
RPg Family Wealth Advisory sold 1,500 Acadia Pharmaceuticals shares in Q3 2017, an estimated $41.8K.
RPg Family Wealth Advisory first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 6 quarters.
RPg Family Wealth Advisory's Acadia Pharmaceuticals position peaked at $64.9K in Q2 2016.
212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on RPg Family Wealth Advisory's 13F filing for Q3 2017, filed 8 Nov 2017.